Merck signs two licensing deals for HIV drug candidates
Linkedin

Merck signs two licensing deals for HIV drug candidates

Toronto : Canada | Jul 25, 2012 at 4:48 AM PDT
Source: Pharmaceutical Industry News
XX XX
Views: Pending
 
Under the agreement with Chimerix, Merck will be responsible for development and commercialization of CMX157, an investigational oral nucleoside reverse transcriptase inhibitor currently in Phase I clinical development. EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) is a novel nucleoside... FULL ARTICLE AT Pharmaceutical Industry News
 
  • Clear
  • Share:
  • Share
  • Clear
  • Clear
  • Clear
  • Clear
 
 
Advertisement
 
Advertisement
 

More From Allvoices

 
Tap_logo_330_110_event
 


Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc 2008-2013. All rights reserved.